DANCHURCHAID
18.3.2024 18:07:34 CET | Business Wire | Press release
A coalition of international climate organizations will come together for an event in Copenhagen on the 20 March 2024 to deliver recommendations on integrating climate and development for climate finance to world leaders, ahead of a year of intense negotiations, starting at the Copenhagen Climate Ministerial.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240318208761/en/
Photo: Mathilde Utzon
The year 2024 is of paramount importance for our future. We face an urgent need to handle the climate crisis, within the broader range of Sustainable Development Goals. This year’s high-level meetings leading up to COP29 will focus on climate finance, aiming to address the substantial funding gaps.
To kick-start these discussions DanChurchAid, E3G, the International Institute for Environment and Development, CONCITO, NDC Partnerships, and the UN Foundation are coming together to co-host the virtual and in-person event ‘Integrating Climate and Development for Adaptation Finance’ in Copenhagen on the 20 March, to provide inspiration for the Copenhagen Climate Summit.
“Adaptation finance must be at the heart of the negotiations towards COP29. Adaptation to the consequences of climate change is a question of survival. We need to adapt to a new reality, where droughts, rising sea levels, and heatwaves are becoming increasingly commonplace,” said Secretary General of DanChurchAid, Jonas Nøddekær.
“The countries most vulnerable to climate change have been clear about what they need to adapt to it - more money, on fairer terms and channelled to local people who are best placed to use it. Governments meeting in Copenhagen have a chance to put down a marker for stronger climate outcomes later this year and to show they're taking lower-income nations seriously,” said Ebony Holland, IIED’s nature-climate policy lead.
“The decisions that governments make this year will shape if, how, and how much finance is delivered over the next decade and beyond. We need to make sure that finance is adequate to achieve the Sustainable Development Goals and a climate resilient future for all,” said Cristina Rumbaitis del Rio, Senior Advisor, Adaptation and Resilience, UN Foundation.
“We must be striving for our climate and development goals concurrently and linking the two. For developing countries, adaptation and resilience are both a priority and a tremendous challenge. The NDC Partnership supports countries efforts to raise ambition in ways that are implementable, financeable and help foster more equitable and sustainable development, through effective coordinated support of more than 220 members,” said Pablo Vieira, Global Director of the NDC Partnership.
“Globally, all stakeholders must come together behind a coherent framework for climate finance as presented by the Independent High-Level Group on Climate Finance to massively upscale funding for integrated climate and development action. Country owned climate plans (NDCs) that integrate adaptation and long-term development plans must be turned into investment plans by 2030,” said Chairperson of the Board of CONCITO, Connie Hedegaard.
“The climate and development ministerials have shone a light on the reforms needed to how we do adaptation finance to shift towards more systemic resilience investments. Denmark, Samoa and their co-champions of the adaptation finance vision agreed at last year’s ministerial have a chance to drive a scale up and improvement in adaptation finance over the next couple of years as countries prepare their next climate policy updates,” said Alex Scott, Climate Diplomacy and Geopolitics Programme Lead at E3G
Event details and registration: The event will take place on the 20 March 2024, from 14:00-16:30, at:
DanChurchAid, Meldahlsgade 3, 1613 Copenhagen V, Denmark.
For registration for either online or in-person participation, please send an email to copenhagenevent@dca.dk
For media request please contact Mattias Söderberg, at: msd@dca.dk or +45 29700609.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240318208761/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
